The assessment of CD39+ cells presence specifically in the Tregs population showed an increased frequency of CD39+ cells within the CD3+ CD4+ CD25high CD127low FoxP3+ subset from RR-MS patients compared with controls; this increase was only statistically significant in the patients who underwent immunomodulatory treatment (Fig. 3c). This evidence concerns the gene ENTPD1 and myeloid sarcoma.